This bill creates a formal partnership between two federal agencies—the Patent and Trademark Office (which handles patent applications) and the Food and Drug Administration (which approves drugs and biological products). The goal is to help patent examiners make better decisions by sharing relevant information with the FDA.

Here's what happens in practice: When someone applies for a patent on a new drug or biological product, the patent examiner can now request information from the FDA about that product—like when it was approved, what it's used for, or recent label changes. This helps the examiner determine whether the invention is truly new and hasn't already been publicly available. The two agencies will also hold regular meetings and training sessions to understand how each other works and share information about new approvals, technologies, and scientific trends.

The bill includes strong privacy protections. Before the FDA shares any confidential information about a drug company's product, that company gets 30 days' notice and a chance to object. The patent office must keep any confidential information separate from public patent files and has procedures to prevent accidental disclosure. Both agencies will create detailed protocols to safeguard sensitive business information.

Within four years, the Patent Office must report to Congress on how often information is actually being shared, which types of information are most helpful to patent examiners, and whether similar partnerships should be created with other federal agencies. The bill doesn't change how the FDA approves drugs or how patents are enforced in court—it simply improves communication between the two agencies to make the patent examination process more informed and accurate.